Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 28, 2019

Primary Completion Date

December 4, 2019

Study Completion Date

February 19, 2020

Conditions
Hepatitis C Virus Infection
Interventions
DRUG

SOF/VEL/VOX

Administered once daily with food.

Trial Locations (10)

20122

Servizio di Epatologia e Nutrizione Pediatrica, Milan

20157

US Infettivologia Pediatrica-Polo Universitario, Milan

50139

SOS-intraSOC Epatologia, Florence

71013

UOSD Epatologia, San Giovanni Rotondo

80131

UOS Epatologia Pediatrica, Napoli

85-030

Wojewodzki Szpital, Bydgoszcz

60-693

Med Polonia, Poznan

50-368

Uniwersytecki Szpital Kliniczny im., Wroclaw

B4 6NH

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

SE5 9RS

Kings Healthcare NHS Trust Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY